Navigation Links
Hologic to Participate in Three Investor Conferences
Date:11/10/2010

BEDFORD, Mass., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX) today announced that company management will participate in the following conferences:

  • Rob Cascella, President and Chief Executive Officer, will present at the J.P. Morgan SMid Conference in New York City on Thursday, December 2, 2010, at 4:30 p.m. (Eastern). Interested parties are invited to listen to the live audio webcast of Hologic's investor presentation on the investor section of the company's website at www.hologic.com/investors-overview. An archive of the presentation will be available for replay following the conference.
  • Glenn Muir, Executive Vice President and Chief Financial Officer, will host investor meetings at the Lazard Capital Markets Medical Technology Corporate Access Day in Denver on Thursday, December 2, 2010. Management will not be presenting at this conference and therefore there will be no webcast.
  • Deborah Gordon, Vice President of Investor Relations, will host investor meetings at the Nasdaq OMX 25th Investor Program in London on Tuesday, December 7, 2010. Management will not be presenting at this conference and therefore there will be no webcast.

  • About Hologic, Inc.Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.Contact:

    Deborah GordonVice President, Investor RelationsHologic, Inc.(781) 999-7716
    '/>"/>

    SOURCE Hologic, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
    2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
    3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
    4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
    5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
    6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
    7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
    8. Hologic Expands Healthcare Investment in Asia
    9. Hologic to Host Investor Reception at RSNA 2009
    10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
    11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
    (Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
    (Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve ... engagement.” The patient is doing more than filling out a survey; in many cases ... an increasing emphasis in health care and research on the importance of active engagement ...
    (Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
    (Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
    (Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
    (Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
    Breaking Medicine News(10 mins):